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1. Introduction  
More than 20 million Americans suffer, and ultimately die, from chronic kidney disease 
(CKD). Based on data from the National Institute of Diabetes and Digestive and Kidney 
Diseases (NIDDK), the yearly cost of dialysis treatment of patients with end stage renal 
disease (ESRD) is currently $35 billion [1], and this number is predicted to rise as the US 
population ages and more people develop obesity, metabolic syndrome, and diabetes. CKD 
is associated with progressive renal fibrosis and inflammation, and currently there is no cure 
for the disease.  
The most common primary illnesses which result in end stage renal disease (ESRD) are 
diabetes (~37%), hypertension (~24%), glomerulonephritis (~15%), cystic kidney diseases 
(~4.7%) and urologic diseases (2.5%) [1]. There were 111,000 new ESRD patients diagnosed 
in 2007 and out of a total of ~500,000 ESRD patients 368,500 people received dialysis 
treatment in the same year. Dialysis patients have poor quality of life due to high 
hospitalization rate (458/1000 patients in 2008), high morbidity and mortality (~20%) [1]. 
Presently, kidney transplant is the only option for these patients to have a close to normal 
life. According to the US Renal Data System 2010 [1] however, out of the ~85,000 patients 
awaiting transplant about 18,000 will receive kidney since the amount of available organs 
did not increase significantly above this number for several years.  
Angiotensin converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers 
(ARBs) are widely used to attenuate the development of cardiovascular diseases and 
support renal function in CKD patients. However, novel therapeutic targets are desperately 
needed to effectively treat CKD and slow down disease progression.  
Currently, there are about 2,000 clinical trials worldwide addressing some aspects and/or 
co-morbidities of CKD [2]. These include treatment of anemia, hypertension, secondary 
hyperparathyroidism, depression and inflammation among others. So far increasing 
frequency and quality of dialysis did not show advantages in survival rate [2]. Similarly, 
treatments targeting hypercholesterolemia [3] and hyperhomocysteinemia [4] or the usage 
of statins [5] failed to increase significantly the survival of ESRD patients.  
In recent years, we and others obtained exciting new data on the pathophysiological role of 
the disintegrin and metalloenzyme ADAMs in renal fibrosis and CKD. This chapter is 
dedicated to summerize these discoveries and discuss their significance and potential role in 
the future treatment of patients with renal diseases. 
www.intechopen.com
 Chronic Kidney Disease 
 
2 
2. Physiology of ADAMs and ADAMTS  
ADAMs (a disintegrin and metalloenzymes) and ADAMTS (ADAMs with thrombospondin-
1-like domains) are membrane-bound multidomain proteins similar to snake venom 
metalloenzymes and disintegrins. Both groups have pro-, metalloenzyme-like, disintegrin-
like and cysteine-rich domains, but compared to ADAMs ADAMTS do not possess 
cytoplasmic or transmembrane regions. Catalytically active ADAMs are Zn2+-dependent 
endopeptidases and are best known for their sheddase activity. They cleave epidermal 
growth factor ligands, cytokines and their receptors, adhesion molecules and the infamous 
amyloid precursor protein among others [6]. ADAMs participate in interreceptor crosstalk 
between G protein coupled receptors (like angiotensin receptors [7], bradykinin receptors [8] 
and serotonin receptors [9]) and members of the tyrosine kinase receptors (epidermal 
growth factors receptor, tumor necrosis factor receptor) by shedding membrane-bound pro-
forms of tyrosine kinase ligands (Figure 1). ADAMs are indispensable for normal 
development, cell proliferation and growth however, at the same time, they can drive 
pathological cell division and inflammation and have major role in the development of 
several proliferative and inflammatory diseases [8]. Some of the ADAMs have mutation in 
their so-called hemopexin-domain (HEXXHXXGXXH) which is responsible for the Zn2+-
binding of the protein. These ADAMs are catalytically inactive and may have a role in cell-
matrix and cell-cell interactions rather than in proteolytic processes [11].  
 
Fig. 1. ADAMs participate in inter-receptor crosstalk: triple membrane spanning signalling. 
AII: angiotensin-II, BK: bradykinin; GPCR: G protein-coupled receptor; mGF: membrane-
bound growth factor, sGF: soluble growth factor; EGFR: epidermal growth factor receptor. 
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ADAMTSs are secreted proteins which anchor to extracellular matrix molecules through 
their thrombospondin-1 domain [12] and are involved in proteolytic cleavage of 
proteoglycans [13], and of the von Willebrand factor [14]. Both protein families can have 
significant contribution to CKD progression. 
2.1 Expression of ADAM enzymes in the normal kidney 
There are several ADAM and ADAMTS proteins which expression was shown in the human 
or murine kidney by various techniques. Histochemical analysis showed that ADAM9 was 
expressed in the nephron: both in the glomerulus and in tubular epithelial cells [15]. 
Expression of a short form of the enzyme lacking the cytoplasmic region was also reported 
in the kidney [16]. ADAM10 expression was first shown in chick kidney [17], in mouse 
kidney of mesenchymal origin [18] and later in humans in the distal tubule, in the 
connecting tubule, in the principal cells of the collecting duct and in the thick ascending 
limb of Henle [19]. ADAM11, which is known as a disintegrin metalloenzyme primarily 
expressed in the central and peripheral nervous system, was also expressed in the epithelial 
cells of the collecting duct at a low level [20]. Since ADAM11 is differentially expressed 
during development, it may have an important role in normal kidney morphogenesis. There 
is also data on the expression of ADAM13 mRNA in the developing mouse kidney [21]. 
ADAM17 is a disintegrin metalloenzyme which is ubiquitously expressed in almost all 
mammalian cells. It is present in the kidney [22] and its expression is upregulated in various 
renal diseases in humans [23]. The mRNA of ADAM19 was present in developing human 
kidney, and in the endothelial cells and in cell of the distal tubules of the adult kidney [23]. 
Expression of ADAM31, another proteolytically active disintegrin metalloenzyme was also 
identified in the epithelium of the convoluted tubuli [24]. High mRNA level of mouse 
ADAM33 was also shown in the kidney [25]. Since this protein is catalytically inactive, it 
may have a role in cell-cell interaction and communication. 
Of the ADAMTS proteins ADAMTS-1 is expressed at high levels in the adult mice kidney 
[26], and in situ hybridization showed high level of ADAMTS-1 in the epithelia of the 
developing kidney [27]. In the rat higher level of ADAMTS-1 was observed in the adult 
animals compared to newborns, and expression pattern of the protease was restricted to the 
renal medulla and the principal cells of the collecting ducts in the kidney [28]. ADAMTS-5 
was observed in glomerular mesangial cells [29]. ADAMTS-9 [30] and ADAMTS-10 [18] are 
highly expressed in the developing and adult kidney, respectively, similarly to human 
ADAMTS-14, -15, -16 [31] with no known function at the present.  ADAMTS-13 was shown 
in healthy human kidney samples and in kidneys of patients with thrombotic 
thrombocytopenic purpura by real-time PCR and immunohistochemistry. ADAMTS-13 was 
present in the glomeruli as well as in the tubuli [32]. Also, various transcripts of ADAM16 
were shown in the developing human and rat kidneys [33, 34]. 
2.1.1 ADAM and ADAMTS in kidney development - what we learned from knockout 
studies  
There is very few data available on the role of ADAMs and ADAMTS enzymes in kidney 
development. There is evidence that expression pattern of ADAMTS-1 [27] and ADAM10 
[35] and ADAM13 [21] changes in the kidney during development and that ADAMTS-9 is 
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highly expressed in the mesenchyme of the developing kidney [30]. However, as of present, 
there is no detail about how knocking down ADAMs influence kidney development.  
Targeted knockout of Adamts-1 in mice showed that the enzyme has an important role in 
kidney development.  Deletion of exon 2 (encoding part of the metalloenzyme domain) 
resulted in lack of ADAMTS-1 protein in mice and high perinatal lethality of the animals 
due to kidney malfunction [36]. In these animals both the cortical and medullary areas were 
reduced with concomitant increase in the caliceal space. Another group found that lack of 
the whole metalloenzyme domain (deletion of exon 2-4) rendered ADAMTS-1 catalytically 
inactive which resulted in enlarged renal calices and fibrosis of the uteropelvic junction [37]. 
These animals also developed bilateral hydronephrosis and papillary atrophy shortly after 
birth [38]. Since normally there is a high level of ADAMTS-1 expressed in the epithelium of 
the collecting ducts and of the uteropelvic junction, and because the phenotype greatly 
resembles to symptoms of the human uteropelvic obstruction, these animals can be good 
models for this genetic disease. 
These data also show that targeting strategies can greatly influence the evolving 
phenotypes. 
3. ADAMs and ADAMTSs in chronic kidney diseases  
3.1 ADAMs in diabetic nephropathy 
There is increasing evidence on the pathophysiological role of ADAM17 (TACE), ADAM19, 
ADAMTS-13 in CKD.  
ADAM17 is a most well-studied sheddase enzyme. It was originally identified as the tumor 
necrosis factor (TNF)- converting (or activating) enzyme [22] or TACE. It cleaves cell 
surface molecules, most importantly cytokines and growth factors [39]. By activating EGFR 
ligands and TNF- ADAM17 has a central role in inflammatory and proliferative processes 
both of which have crucial role in the development of CKD (Figure 2).  
 
Fig. 2. Role of ADAM17 in CKD. 
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Besides initiating inflammation, TNF has important pathophysiological role in insulin 
resistance (reviewed in [40]). After activation by ADAM17, the soluble homotrimer of TNF 
activates the TNF receptor and downstream signaling molecules. Activation of the MAP 
kinase pathway initiates serine phosphorylation of the insulin receptor substrate (IRS) 
intracellularly. Being phosphorylated on serine inhibits tyrosine phosphorylation of the IRS 
which results in insensitivity of the insulin receptor to extracellular insulin and contributes 
the development of diabetes (Figure 3). 
 
Fig. 3. Mechanism of TNF-induced insulin resistance 
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High glucose was also shown to promote heparin-binding growth factor (HB-EGF) 
shedding through ADAM17 activation, however the exact mechanism is unknown [41]. 
Since ADAM17 activates secretion of TNF, pharmacological inhibitors of the enzyme were 
tested on blood glucose regulation in animal model of non-obesity-related insulin resistance 
(fructose-fed rats). ADAM17 inhibitor restored the animals’ insulin resistance [42]. In 
another study, animals heterozygous for ADAM17 (+/-) proved to be relatively protected 
from high-fat diet-induced obesity and diabetes [43].  
A close structural relative of ADAM17, ADAM10 is involved in shedding of RAGE: receptor 
for advanced glycation end products [44]. Since soluble RAGE can block pathophysiological 
processes initiated by RAGE, ADAM10 activation may slow down development of diabetes.  
As of today, we do not have data on the pathophysiological role of ADAMTS enzymes in 
diabetes mellitus. 
3.2 ADAMs in renal transplant dysfunction and ischemia reperfusion injury 
In vitro studies modelling mechanisms of transplant rejection showed that the mRNA 
expression of ADAM17 was upregulated in the kidney and that the protein expression of 
the enzyme was localized next to TNF receptor II. This suggested that ADAM17 may 
antagonize the effect of TNF by shedding of its receptor during transplant rejection and 
therefore higher ADAM17 activity might be beneficial [45]. On the other hand, ADAM17 
also co-localized with HB-EGF in experimental ischemia-reperfusion injury which suggested 
that increased shedding of the growth factor may have contributed to the observed fibrotic 
injury [46]. Pharmacological inhibitors targeting ADAM17 activity reduced renal tissue 
injury associated with reperfusion. This confirmed that the increased enzyme activity was a 
cause rather than the consequence of the tissue injury [47].  
Another ADAM enzyme, ADAM19 was also implicated in allograft nephropathy however, 
we do not know any mechanistic details of its actions [48].  
3.3 ADAMs in renal fibrosis 
Renal fibrosis is a manifestation of several pathological processes. Glomerular fibrosis can 
be induced by over-activation of the renin-angiotensin system, and the developing fibrosis 
and inflammation can be successfully attenuated by ADAM17 inhibitors in animal models 
of the injury [7].  We showed previously that serotonin-induced mesangial cell proliferation, 
which is an important component of glomerular fibrosis, can be inhibited by knocking down 
ADAM17 expression and inhibiting the enzyme activity [9]. On the other hand, we also 
found that ADAM17 can protect glomerular function by decreasing podocyte permeability 
through inducing re-arrangement of the zonula occludens protein ZO-1 [8]. These data 
suggest that depending on the cellular context the enzyme can have different effect on the 
renal function. Nonetheless, inhibitors of ADAM17 decreased infiltration of macrophages 
both in the glomeruli and in the interstitium in models of kidney fibrosis [7, 46] proving that 
targeting ADAM17 can be beneficial for preserving renal function.  
There is very few data available on ADAMTS enzymes and renal fibrosis. Unilateral ureteral 
obstruction in rat induced upregulation of ADAMTS-1 in the tubular epithelial cells. Further, 
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secreted ADAMTS-1 of cultured epithelial cells decreased proliferation of a tubular fibroblast 
cell line which suggested that ADAMTS-1 may have anti-fibrotic effect [49]. 
3.4 ADAMs in polycystic kidney disease (PKD) 
Autosomal-recessive polycystic kidney disease (AR-PKD) is one of the most common genetic 
disorders of the kidney results in end-stage renal disease. This disease leads to rapid 
enlargement of the kidney through massive cysts formation. The main pathogenic process in 
cyst development is the overactivation of the mislocalized EGFR in the cystic apical epithelia 
(for review see [50]). Excessive shedding of the pro-proliferative growth factor, transforming 
growth factor (TGF) was also observed. Since secretion of TGFis regulated by ADAM17, 
therapeutic potential of ADAM17 inhibitors were explored and established in the bpk murine 
model of AR-PKD [51]. In a later study, the role of TGF was not confirmed even if ADAM17 
inhibitors were beneficial for attenuating cyst development in AR-PKD [52]. 
3.5 Thrombotic thrombocytopenic purpura (TTP)/ haemolytic-uremic syndrome (HUS) 
Thrombotic thrombocytopenic purpura/haemolytic uremic syndrome are often considered 
variants of a disease characterized by microangiopathic haemolytic anaemia [53]. Platelets 
are consumed by spontaneously developing microscopic thrombosis. ADAMTS-13, the 
enzyme which normally processes the very large von Willebrand factor (vWF) is missing 
[54] or disabled [55, 56] in this disease. Therefore, the very large vWF “capture” circulating 
platelets and initiates microthrombi formation. The red blood cells passing through the 
damaged arteries experience excessive shear stress which leads to haemodialysis. Besides 
purpura and anaemia there are often fever and neurologic symptoms present and the 
disease can lead to both acute kidney failure and CKD [57, 58]. Interestingly, a recent study 
which investigated plasma level of vWF in patients with chronic kidney disease of different 
origin found decreased level of vWF-cleaving protease [59]. Level of vWF was higher in 
stage IV patients compared to stages II and III, but whether the increased vWF contributed 
to the worsening of CKD is currently not known. 
4. ADAMs in kidney cancer 
Several ADAM enzymes were upregulated at the message level in human renal cell 
carcinomas. Compared to normal tissue mRNA levels of ADAM8, -17, -19, -28 as well as 
ADAMTS-2 were upregulated. Interestingly, mRNA level of ADAMTS-1 did not change 
[60]. In other studies, ADAM10 [61] and ADAM9 expression was increased in renal cancer 
cells and associated with tumor progression [62] suggesting that expression of these enzyme 
may be used as tumor markers. ADAM15 and -17 contributed to the migratory potential of 
kidney cancer cells through activation of the EGFR [63] and ADAM17 silencing disabled the 
capability of renal carcinoma cells to form in vivo tumors [64]. Therefore these enzymes 
seem to have direct role in renal cancer pathophysiology. 
5. Conclusion 
ADAM and ADAMTS families include growing number of metalloenzymes which have 
important role in kidney development and are indispensable to normal kidney function. 
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Lack or overactivation of certain ADAM enzymes (especially ADAM17 and ADAMTS-13) 
can have major pathophysiological role in development of various type of CKD. Therefore, 
targeting these enzymes can be an exciting novel therapeutic approach in the future and a 
new hope for CKD patients. 
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